

**South Zone East Hospitals – Medicine Hat, Brooks, Bassano, Bow Island, Oyen
January 1 – December 31, 2013 Cumulative Antimicrobial Susceptibility Report (% Susceptible)**

	No. of Isolates	Ampicillin Amoxicillin	Ceftriaxone	Ceftazidime	Cephalothin Cephalexin	Ciprofloxacin	Clindamycin	Erythromycin	Gentamicin	Gentamicin Synergy Screen	Nitrofurantoin (Urinary isolates only)	Oxacillin Cloxacillin	Penicillin	Piperacillin	Sulfamethoxazole /Trimethoprim	Tobramycin	Vancomycin
<i>Citrobacter species*</i>	31	R	-	-	-	97	-	-	97	-	71	-	-	-	97	-	-
<i>Enterobacter species*</i>	42	R	-	-	R	98	-	-	100	-	26	-	-	-	95	-	-
<i>Escherichia coli</i>	1042	60	95	-	60 ^U	87	-	-	94	-	90	-	-	-	79	-	-
<i>Klebsiella oxytoca</i>	40	R	95	-	85 ^U	100	-	-	100	-	75	-	-	R	98	-	-
<i>Klebsiella pneumoniae</i>	150	R	99	-	93 ^U	98	-	-	100	-	39	-	-	R	95	-	-
<i>Proteus mirabilis</i>	53	79	94	-	94 ^U	92	-	-	94	-	R	-	-	-	85	-	-
<i>Pseudomonas aeruginosa</i>	67	R	R	93	R	85	-	-	83	-	R	-	-	80	R	93	-
<i>Enterococcus faecalis</i>	126	99	R	R	R	71 ^U	R	-	R	73	87	-	-	-	R	R	100
Group A Streptococcus ^{1,2}	54	-	-	-	-	-	65 ^P	70 ^P	-	-	-	-	100	-	R	-	-
Group B Streptococcus	38	-	-	-	-	-	53 ^P	58 ^P	-	-	-	-	100	-	R	-	-
<i>Staphylococcus aureus</i>	370	-	-	-	78	-	-	-	-	-	97	78	19	-	98	-	100
MRSA Subset (22%) ³	82	-	-	-	R	-	38	22	-	-	95	R	R	-	99	-	100
MSSA Subset (78%) ³	288	-	-	-	100	-	89	86	-	-	98	100	24	-	98	-	100
<i>Streptococcus pneumoniae</i>	41	-	-	-	-	-	-	-	-	-	-	-	89	-	-	-	-

- Antimicrobial not tested or antimicrobial not indicated.

* These organisms usually produce inducible beta-lactamase which may cause failure of penicillin/cephalosporin therapy, despite an in-vitro susceptible result.

R Organism is intrinsically resistant to indicated antimicrobial.

1 Superficial skin and soft-tissue isolates only.

2 Due to the small number of annual isolates, analysis was performed using data obtained during the 2 year period of January 1, 2012 – December 31, 2013

3 MRSA (Methicillin Resistant *Staphylococcus aureus*); ⁴MSSA (Methicillin Susceptible *Staphylococcus aureus*)

U Data for this antimicrobial/organism combination is applicable for use towards treatment of urinary tract infections only. Please note that results of Cephalothin/Cephalexin testing for *E. coli*, *Klebsiella* species, and *Proteus mirabilis* do not reliably predict clinical outcome when Cephalexin is used to treat superficial skin and soft-tissue infections.

P Treatment using Macrolides (Erythromycin/Clarithromycin/Azithromycin) or Lincosamides (Clindamycin) is generally not recommended except when treatment using Penicillin is contraindicated.

Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate only of that organism recovered from a given patient during the time period analyzed.